Abstract
The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) demonstrated a heightened risk of stroke associated with Darbepoetin alfa (DA) use. Although stroke was not a primary endpoint, this finding raised significant patient safety concerns. The Reduction of Events by Darbepoetin Alfa
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
